Big Medical Breakthroughs Start With Small Gains – Inside Sources

A new experimental drug for pancreatic cancer, daraxonrasib, appears to have extended the lives of some patients with advanced disease by several months, according to clinical trial results out last month.

That may not sound like much. For someone facing a terminal diagnosis, what difference does a few extra months really make, especially if the drugs that enable them cost tens of thousands of dollars, as so many cancer drugs do?

That question misses the point. In medicine, the most important breakthroughs rarely arrive all at once. They are built step by step. First, we gain a few extra months, then a few more, then years, until the disease in question is eradicated.

If we dismiss those early gains as too expensive, the larger breakthroughs they make possible may never come.

Consider HIV. When the Food and Drug Administration approved AZT in 1987, it was no miracle cure. The drug extended patients’ lives, but only modestly. By today’s standards, some might have judged it too expensive for the benefit it delivered.

That would have been a catastrophic mistake.

AZT was the first step in a long chain of advances in how we treat HIV/AIDS. Over time, researchers improved upon it, combined it with other therapies, and refined treatment strategies. Today, highly active antiretroviral therapy has transformed HIV from a death sentence into a manageable chronic condition.

Millions of people are alive today because scientists built on those early, imperfect gains.

The same pattern shows up across medicine.

Take childhood leukemia. In the 1950s, the disease was almost universally fatal. Early treatments could put patients into remission, but most relapsed quickly. Researchers kept iterating: improving drugs, combining therapies and refining protocols. Today, 90 percent of children diagnosed with leukemia survive.

Drug development is inherently uncertain and expensive. Bringing a single medicine to market costs, on average, about $2.6 billion. Only about one in 10 drugs that enter clinical trials ever reach patients.

Given those odds, it’s fair to ask: Why invest so much in therapies that initially offer only modest benefits?

Because that’s how cures come about.

Policymakers often ignore this reality. Influential organizations like the Institute for Clinical and Economic Review routinely judge new treatments against rigid “cost-effectiveness” thresholds, often discounting therapies that extend life by only a few months.

Some critics dismiss new therapies as “me-too” drugs that offer only marginal health improvements for high prices.

That thinking is dangerously shortsighted.

Consider PCSK9 inhibitors, a newer class of cholesterol drugs. When they first came to market, critics argued they were not cost-effective relative to their benefits. Over time, however, evidence showed they could significantly reduce the risk of heart attacks and strokes in high-risk patients, an advance that built directly on decades of incremental progress in cardiovascular care.

Current generations of drugs must generate the returns needed to fund future research, including the incremental advances that ultimately lead to major breakthroughs. Undervalue those early steps, and the entire pipeline of innovation begins to dry up.

The consequences would be felt most acutely in areas like pancreatic cancer, which kills about seven in eight people within five years of diagnosis. A treatment that buys a few months today could lead to one that buys several years or more down the line.

If early stage advances are dismissed as not worth the cost, investment will shift away from the very diseases that demand the most scientific risk-taking.

The United States leads the world in biopharmaceutical innovation because it rewards that risk-taking. Our system encourages steady, cumulative progress. Tomorrow’s miracle cures will be the product of many small gains that may have seemed insignificant — or even cost-ineffective — at the time.

Daraxonrasib may not be a cure for pancreatic cancer. But it could be the first step toward one, the kind of step that has led to countless major medical breakthroughs.